Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. NVDA
3. META
4. SPY
5. MSFT
6. DCOY
7. VKTX
8. PRGS
9. WOR
10. LGND

Go back to Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals (ALNY) PT Lowered to $175 at BMO Capital

February 11, 2022 7:21 AM EST

BMO Capital analyst Gary Nachman lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $175.00 (from $180.00) while maintaining a Market Perform rating.

The analyst commented, "Solid 4Q product revenue was preannounced as key commercial products (Onpattro/Givlaari/Oxlumo) continue good momentum with increased... More

Alnylam Pharma (ALNY) Misses Q4 EPS by 13c

February 10, 2022 8:07 AM EST

Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.69), $0.13 worse than the analyst estimate of ($1.56). Revenue for the quarter came in at $258.5 million versus the consensus estimate of $231.44 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

... More